POL research ethics
K |
|||
Zeile 1: | Zeile 1: | ||
+ | publication issues will appear in specific threads later currently here | ||
+ | |||
{{tp|p=29412966|t=2018. Ban on gain-of-function studies ends.|pdf=|usr=015}} | {{tp|p=29412966|t=2018. Ban on gain-of-function studies ends.|pdf=|usr=015}} | ||
{{tp|p=32218549|t=2020. Should scientists infect healthy people with the coronavirus to test vaccines?|pdf=|usr=018}} | {{tp|p=32218549|t=2020. Should scientists infect healthy people with the coronavirus to test vaccines?|pdf=|usr=018}} | ||
Zeile 30: | Zeile 32: | ||
{{tp|p=32467100|t=2020. Research on covid-19 is suffering "imperfect incentives at every stage".|pdf=|usr=007}} | {{tp|p=32467100|t=2020. Research on covid-19 is suffering "imperfect incentives at every stage".|pdf=|usr=007}} | ||
{{tp|p=32469074|t=2020. Paying Participants in COVID-19 Trials.|pdf=|usr=007}} | {{tp|p=32469074|t=2020. Paying Participants in COVID-19 Trials.|pdf=|usr=007}} | ||
− | + | {{tp|p=32473068|t=2020. Profile and quality of published reviews on COVID-19.|pdf=|usr=007}} | |
+ | {{tp|p=32479113|t=2020. Modeling compliance with COVID-19 prevention guidelines: the critical role of trust in science.|pdf=|usr=007}} | ||
{{tp|p=32414757|t=2020. Ethical considerations for epidemic vaccine trials.|pdf=|usr=007}} | {{tp|p=32414757|t=2020. Ethical considerations for epidemic vaccine trials.|pdf=|usr=007}} | ||
+ | {{tp|p=32479747|t=2020. COVID-19 human challenge studies: ethical issues.|pdf=|usr=009}} | ||
+ | {{tp|p=32496536|t=2020. SARS-CoV-2 Human Challenge Trials: Too Risky, Too Soon.|pdf=|usr=007}} | ||
+ | {{tp|p=32499292|t=2020. Covid-19: Validity of key studies in doubt after leading journals issue expressions of concern.|pdf=|usr=007}} | ||
+ | {{tp|p=32504015|t=2020. Will the pandemic permanently alter scientific publishing?|pdf=|usr=007}} | ||
+ | |||
+ | {{tp|p=32487103|t=2020. The crucible of COVID-19: what the pandemic is teaching us about health research systems.|pdf=|usr=008}} | ||
+ | {{tp|p=32495919|t=2020. Representation of specialties in Coronavirus Disease 2019 (COVID-19) research: analysis of published literature in the first 3 months.|pdf=|usr=007}} | ||
+ | {{tp|p=32496027|t=2020. Fast news or fake news?: The advantages and the pitfalls of rapid publication through pre-print servers during a pandemic.|pdf=|usr=008}} | ||
+ | {{tp|p=32504025|t=2020. High-profile coronavirus retractions raise concerns about data oversight.|pdf=|usr=007}} | ||
+ | |||
+ | {{tp|p=32487369|t=2020. Balancing the need for rapid and rigorous scientific data during early phase of the COVID-19 pandemic: A further role for the scientific community.|pdf=|usr=008}} | ||
+ | |||
+ | {{tp|p=32506512|t=2020. Redundancy and methodological issues in articles on COVID-19.|pdf=|usr=007}} | ||
+ | {{tp|p=32507366|t=2020. Scientific Publications During the COVID-19 Pandemic.|pdf=|usr=007}} | ||
+ | {{tp|p=32532740|t=2020. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review.|pdf=|usr=008}} | ||
+ | {{tp|p=32559417|t=2020. Overcoming fragmentation of health research in Europe: lessons from COVID-19.|pdf=|usr=010}} | ||
+ | {{tp|p=32559649|t=2020. Prejudice in science - Lessons from the coronavirus story.|pdf=|usr=011}} | ||
+ | |||
+ | {{tp|p=32480419|t=2020. Conquest of COVID-19. Publish it to Death?|pdf=|usr=007}} | ||
+ | {{tp|p=32532662|t=2020. Need for innovative and timely synthesis of evidence during Covid-19 outbreak.|pdf=|usr=008}} | ||
+ | {{tp|p=32532663|t=2020. The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence.|pdf=|usr=008}} | ||
+ | |||
+ | {{tp|p=32513798|t=2020. The good, the bad & the hoax: when publication instantaneously impacts treatment strategies for COVID-19.|pdf=|usr=008}} | ||
+ | {{tp|p=32515402|t=2020. Publishing research during pandemics: are you vulnerable to the COVID-19 or predatory publishers?|pdf=|usr=008}} | ||
+ | {{tp|p=32525104|t=2020. Publishing in the time of pandemic: Editorial policy of a dermatology journal during COVID-19.|pdf=|usr=008}} | ||
+ | |||
+ | |||
+ | {{tp|p=32511943|t=2020. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.|pdf=|usr=007}} |
Version vom 6. Dezember 2020, 10:36 Uhr
publication issues will appear in specific threads later currently here
29412966 2018. Ban on gain-of-function studies ends.
32218549 2020. Should scientists infect healthy people with the coronavirus to test vaccines?
32241929 2020. Infect volunteers to speed a coronavirus vaccine?
32322034 2020. Hundreds of people volunteer to be infected with coronavirus.
32354694 2020. The COVID-19 pandemic, personal reflections on editorial responsibility.
32367890 2020. COVID-19 and Transnational Issues in Copyright and Related Rights.
32373785 2020. Data sharing in the era of COVID-19.
32378373 2020. A publishing pandemic during the COVID-19 pandemic: how challenging can it become?
32378390 2020. Meta-analysis is not always the best way to round out a systematic review: a few thoughts prompted by the COVID-19 pandemic and "spiced-up" with an earthquake.
32379854 2020. Biomedical Research in Times of Emergency: Lessons From History.
32382120 2020. How swamped preprint servers are blocking bad coronavirus research.
32382121 2020. Autopsy slowdown hinders quest to determine how coronavirus kills.
32398241 2020. Waste in covid-19 research.
32402511 2020. COVID-19 Ethics and Research.
32405095 2020. Assessing changes in US public trust in science amid the COVID-19 pandemic.
32407142 2020. Producing Independent, Systematic Review Evidence: Cochrane's Response to COVID-19.
32407155 2020. Publication Ethics During Public Health Emergencies Such as the COVID-19 Pandemic.
32412540 2020. Herausforderungen und Chancen fur die Arbeit der Akademie fur Ethik in der Medizin angesichts der COVID-19-Pandemie.
32413197 2020. Scientific Editing in the COVID-19 Era-Personal Vignettes from the JBMR Editors.
32414291 2020. Fake Science: XMRV, COVID-19, and the Toxic Legacy of Dr. Judy Mikovits.
32422983 2020. No Autopsies on COVID-19 Deaths: A Missed Opportunity and the Lockdown of Science.
32423900 2020. Alarm bells ring for patient data and privacy in the covid-19 goldrush.
32433777 2020. Queries on the COVID-19 quick publishing ethics.
32440022 2020. Scientists baffled by decision to stop a pioneering coronavirus testing project.
32441125 2020. Time-Out Protocol to Ensure Understanding and Implementation of the Storm of Instructions and Protocols During the COVID-19 Pandemic.
32450986 2020. Research and Publishing in the COVID-19 Pandemic.
32457027 2020. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review.
32461245 2020. Ethical guidelines for deliberately infecting volunteers with COVID-19.
32464320 2020. 'One more time': why replicating some syntheses of evidence relevant to COVID-19 makes sense.
32467100 2020. Research on covid-19 is suffering "imperfect incentives at every stage".
32469074 2020. Paying Participants in COVID-19 Trials.
32473068 2020. Profile and quality of published reviews on COVID-19.
32479113 2020. Modeling compliance with COVID-19 prevention guidelines: the critical role of trust in science.
32414757 2020. Ethical considerations for epidemic vaccine trials.
32479747 2020. COVID-19 human challenge studies: ethical issues.
32496536 2020. SARS-CoV-2 Human Challenge Trials: Too Risky, Too Soon.
32499292 2020. Covid-19: Validity of key studies in doubt after leading journals issue expressions of concern.
32504015 2020. Will the pandemic permanently alter scientific publishing?
32487103 2020. The crucible of COVID-19: what the pandemic is teaching us about health research systems.
32495919 2020. Representation of specialties in Coronavirus Disease 2019 (COVID-19) research: analysis of published literature in the first 3 months.
32496027 2020. Fast news or fake news?: The advantages and the pitfalls of rapid publication through pre-print servers during a pandemic.
32504025 2020. High-profile coronavirus retractions raise concerns about data oversight.
32487369 2020. Balancing the need for rapid and rigorous scientific data during early phase of the COVID-19 pandemic: A further role for the scientific community.
32506512 2020. Redundancy and methodological issues in articles on COVID-19.
32507366 2020. Scientific Publications During the COVID-19 Pandemic.
32532740 2020. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19 pandemic: rapid review.
32559417 2020. Overcoming fragmentation of health research in Europe: lessons from COVID-19.
32559649 2020. Prejudice in science - Lessons from the coronavirus story.
32480419 2020. Conquest of COVID-19. Publish it to Death?
32532662 2020. Need for innovative and timely synthesis of evidence during Covid-19 outbreak.
32532663 2020. The eighth alternative to evidence based medicine in the early era of the COVID-19 pandemic: Too much emergency and emotion, too little evidence.
32513798 2020. The good, the bad & the hoax: when publication instantaneously impacts treatment strategies for COVID-19.
32515402 2020. Publishing research during pandemics: are you vulnerable to the COVID-19 or predatory publishers?
32525104 2020. Publishing in the time of pandemic: Editorial policy of a dermatology journal during COVID-19.
32511943 2020. Retraction-Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.